ALT Altimmune Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALT

Price (delayed)

$2.915

Market cap

$566.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$503.75M

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 32

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), ...

Highlights
The equity has surged by 100% year-on-year and by 26% since the previous quarter
ALT's quick ratio has soared by 92% YoY and by 61% QoQ
ALT's revenue has surged by 140% year-on-year but it is down by 12% since the previous quarter
The gross profit has soared by 140% YoY but it has contracted by 12% from the previous quarter
Altimmune's net income has decreased by 3.4% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.altimmune.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ALT

ALT stock price

How has the Altimmune stock price performed over time
Intraday
1.57%
1 week
-5.05%
1 month
-3.48%
1 year
-46.9%
YTD
-19.25%
QTD
-5.36%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
$36,000
Gross profit
$36,000
Operating income
-$96.92M
Net income
-$91.08M
Gross margin
100%
Net margin
-253,002.8%
ALT's revenue has surged by 140% year-on-year but it is down by 12% since the previous quarter
The gross profit has soared by 140% YoY but it has contracted by 12% from the previous quarter
The operating margin has soared by 59% year-on-year but it has declined by 17% since the previous quarter
The net margin has surged by 58% year-on-year but it has declined by 18% since the previous quarter

Price vs fundamentals

How does ALT's price correlate with its fundamentals

Growth

What is Altimmune's growth rate over time

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
1.34
P/S
10,077.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13,993.17
Altimmune's EPS has increased by 27% YoY and by 8% QoQ
The equity has surged by 100% year-on-year and by 26% since the previous quarter
The P/B is 45% lower than the 5-year quarterly average of 2.4 and 23% lower than the last 4 quarters average of 1.7
ALT's revenue has surged by 140% year-on-year but it is down by 12% since the previous quarter
ALT's P/S is 36% below its last 4 quarters average of 15475.2 but 32% above its 5-year quarterly average of 7501.8

Efficiency

How efficient is Altimmune business performance
Altimmune's return on sales has surged by 59% YoY but it has decreased by 16% QoQ
The company's return on invested capital rose by 44% YoY and by 23% QoQ
ALT's ROA is up by 39% YoY and by 15% QoQ
The return on equity rose by 35% year-on-year and by 14% since the previous quarter

Dividends

What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Altimmune financials performed over time
The total assets has soared by 113% YoY and by 20% from the previous quarter
ALT's quick ratio has soared by 92% YoY and by 61% QoQ
The debt is 88% smaller than the equity
The equity has surged by 100% year-on-year and by 26% since the previous quarter
Altimmune's debt to equity has decreased by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.